X. Meng

发表

Randomized, Open-Label, Multicentre Pharmacokinetic Studies of Two Dose Levels of Pantoprazole Granules in Infants and Children Aged 1 Month through <6 Years with Gastro-Oesophageal Reflux Disease

Kim G. Adcock, J. Kierkuś, R. Ward, 2011, Clinical pharmacokinetics.

Bioequivalence among three methods of administering pantoprazole granules in healthy subjects.

A. Katz, B. Tammara, K. Weisel, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).

A. Ricart, D. Yin, C. Taylor, 2014, British journal of clinical pharmacology.

A Multicenter, Randomized, Open‐Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease

M. Katz, G. Kearns, R. Ward, 2011, Journal of clinical pharmacology.

Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD)

R. Ward, G. Comer, D. Stewart, 2010, European Journal of Clinical Pharmacology.

A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

Stanley B. Cohen, Dolca Thomas, P. Emery, 2016, British journal of clinical pharmacology.

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

A. Katz, M. Burczynski, L. Hickey, 2009, Journal of clinical pharmacology.

Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody–Drug Conjugates

S. Palani, K. Liao, D. Yin, 2022, The AAPS Journal.

Effect of PSI‐697, a Novel P‐Selectin Inhibitor, on Platelet–Monocyte Aggregate Formation in Humans

D. Newby, K. Fox, G. Feuerstein, 2013, Journal of the American Heart Association.

A Mechanism‐Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development

K. Liao, B. Gumbiner, P. Garzone, 2017, Journal of clinical pharmacology.

Comparative tolerability of 2- and 15-minute intravenous infusions of pantoprazole.

P. Fraga, M. Micalizzi, X. Meng, 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Oxycodone hydrochloride controlled‐release tablets (OxyContin®): post‐marketing surveillance (PMS) study for relieving moderate to severe non‐cancer pain

Zhao Guodong, Xu Jianguo, Duan Dongping, 2007 .

Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes

Samantha L. Bucktrout, P. Garzone, T. Joh, 2020, The AAPS Journal.

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

M. Hutmacher, K. Liao, B. Gumbiner, 2016, British journal of clinical pharmacology.